Evidence map›Paper›PMID 38078287›Full record

ArticleLeukemia research reports2024

Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight.

Claudia Ielo, Francesca Fazio, Serena Rocchi, Ilaria Rizzello, Katia Mancuso, Elena Zamagni, Michele Cavo, Maria Teresa Petrucci

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Claudia IeloHematology Unit, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Italy.
Francesca FazioHematology Unit, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Italy.
Serena RocchiSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy.
Ilaria RizzelloSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy.
Katia MancusoSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy.
Elena ZamagniSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy.
Michele CavoSeràgnoli Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy.
Maria Teresa PetrucciHematology Unit, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, immune impairment induced by cellular therapies, previous treatments and MM itself could promote infectious events. COVID-19 could evolve into a life-threating infection in R/R MM patients who often have suboptimal responses to SARS-CoV-2 vaccines. Here, we describe a case of severe and long-lasting COVID-19 pneumonia after CAR T-cell therapy for R/R MM requiring a complex clinical management. Long-term infectious complications in MM patients undergoing CAR T-cells should be taken into consideration as they could counteract the efficacy of this new treatment.

Indexed as

Cellular therapiesInfectious complicationsMultiple myeloma

Identifiers

PMID38078287
PMCPMC10698652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.